DS
RPTP

David Shaw’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

David Shaw’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-931,488
Closed -$8.36M – 3798
2016
Q3 		$8.36M Sell
931,488
-1,019,667
-52% -$7.25M 0.01% 995
2016
Q2 		$10.5M Buy
1,951,155
+94,888
+5% +$486K 0.02% 869
2016
Q1 		$8.54M Sell
1,856,267
-496,356
-21% -$2M 0.02% 947
2015
Q4 		$12.2M Sell
2,352,623
-199,157
-8% -$1.16M 0.02% 882
2015
Q3 		$15.4M Buy
2,551,780
+322,619
+14% +$3.95M 0.02% 729
2015
Q2 		$35.2M Buy
2,229,161
+1,339,131
+150% +$16.3M 0.05% 426
2015
Q1 		$9.68M Buy
890,030
+477,468
+116% +$4.87M 0.01% 981
2014
Q4 		$4.34M Buy
412,562
+44,357
+12% +$433K 0.01% 1682
2014
Q3 		$3.53M Sell
368,205
-64,487
-15% -$659K ﹤0.01% 1803
2014
Q2 		$5M Buy
432,692
+204,422
+90% +$1.86M 0.01% 1631
2014
Q1 		$2.28M Sell
228,270
-80,035
-26% -$1.16M ﹤0.01% 2254
2013
Q4 		$4.01M Sell
308,305
-2,255
-0.7% -$31.1K 0.01% 1886
2013
Q3 		$4.64M Buy
+310,560
New +$3.72M 0.01% 1667

David Shaw's RPTP Position: Q4 2016 in Review

David Shaw sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 931,488 shares — an estimated $8.36M sold.

David Shaw first reported a position in RPTP in Q3 2013 and held it in 13 quarters. The position peaked at $35.2M in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.

  • David Shaw reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
  • David Shaw sold 931,488 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $8.36M.
  • David Shaw first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q3 2013 and held it in 13 quarters.
  • David Shaw's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $35.2M in Q2 2015.
  • 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.

Based on D.E. Shaw & Co's 13F filing for Q4 2016, filed 14 Feb 2017.